Anacor Pharmaceuticals to Present at the Fifth Annual “Resistance is Futile: the Challenge of Antibacterial Drug Developme

PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Dickon Alley, Ph.D., Senior Research Leader, will be presenting at the Fifth Annual “Resistance is Futile: the Challenge of Antibacterial Drug Development” Conference hosted by Drug Discovery Chemistry in San Diego on Tuesday, April 12, 2011 at 4:30 p.m. PT. The subject of Dr. Alley’s presentation is “Tackling Microbial Resistance: Novel Targets Accessed by Boron Antibacterials.” Slides from Dr. Alley’s presentation will be available following the presentation at under News & Events.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds that are currently in development, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK ‘052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit


Anacor Pharmaceuticals, Inc.
DeDe Sheel, 650.543.7575
Director, Investor Relations and Corporate Communications

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  Research  Other Science  Science